Syndax Pharmaceuticals Inc 8-K

What Happened
Syndax Pharmaceuticals, Inc. announced on June 10, 2026 that it completed a private placement issuing $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 (the "Notes"). The Notes were issued under an indenture dated June 10, 2026 between the company and U.S. Bank Trust Company, National Association, as trustee.

Key Details

• Amount issued: $250.0 million aggregate principal of convertible senior notes.
• Interest rate / maturity: 2.25% coupon, due 2031.
• Closing date: June 10, 2026 (private placement).
• Documentation: Notes issued pursuant to an indenture with U.S. Bank Trust Company, N.A. as trustee; related exhibits (indenture and form of global note) are filed as exhibits.
• Related disclosures: The filing also reports the creation of a direct financial obligation and the unregistered sale of equity securities in connection with the Notes.

Why It Matters
This transaction provides Syndax with $250 million of capital, which changes the company’s balance sheet by adding a convertible debt obligation. For investors, the low 2.25% coupon is a relatively inexpensive financing cost, but the convertible feature means the notes could be exchanged for equity in the future, potentially diluting existing shareholders if conversions occur. The filing is material (Item 1.01) because it creates a significant contractual obligation and involves unregistered securities issuance.